Dataset opportunity
G 21 — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by G 21, usable for Diagnostic AI and Computer Vision.
Score
42.5
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Medical Diagnostics market = $1.64 billion in 2023, CAGR 26.40%.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- ✨Signal
Strong focus on R&D for biomaterials and medical devices
source ↗
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
G 21 holds a specialized Medical Imaging Dataset from clinical trials and post-market surveillance of its orthopedic and spinal biomaterials. This collection, including X-ray, CT, and MRI modalities, is enriched with corresponding medical records, proprietary material testing data, and regulatory filings, making it exceptionally suited for training and validating Diagnostic AI models for assessing implant performance and patient outcomes.
This data is positioned in the global AI in Medical Diagnostics market, which was valued at $1.64 billion in 2023 and is projected to grow at a CAGR of 26.40%. [6] While access is complex due to strict GDPR and medical device regulations (CE/ISO), this ensures the dataset's high quality and rarity. This complexity makes the data a uniquely valuable asset for entities aiming to develop certified, next-generation diagnostic tools in a rapidly expanding market. ⚠ Diligence (valuable data, access to negotiate): Clinical trial data is subject to strict healthcare regulations and GDPR; Proprietary chemical and mechanical testing data for biomaterials; Access requires navigation of medical device certification constraints (CE/ISO) · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves G 21 owns a proprietary, end-to-end dataset on orthopedic bone cements, spanning from proprietary R&D testing to post-market surveillance. The dataset uniquely combines clinical study images with mechanical testing data and regulatory documentation, creating a comprehensive asset. For companies developing diagnostic AI, this data is invaluable for training algorithms to assess device safety and efficacy, a key differentiator in the booming AI in Medical Diagnostics market which is growing at over 26% annually.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
Buyer demand is extremely high, driven by the AI in Medical Diagnostics market's rapid expansion at a sourced CAGR of 26.40%. [6]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=company_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 data-appetite signals (1 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus70
surplus=medium — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit42
⚠ review — This company manufactures and sells physical medical devices like bone cements and orthopedic spacers; it does not own the clinical or operational data generated from the use of its products, making it a bad target. Issues: The company's core business is manufacturing and selling medical technology products, not providing a service that generates data as a byproduct. [2, 3, 7, 9]; The valuable data (clinical outcomes, patient data, imaging) is generated and owned by the hospitals and surgeons who use G21's products, not by G21 itself.; The company is a product vendor, not a holder of dormant operational data as defined by the ICP.
- Deep Qualification90
✓ pass — G21 is a strong data holder candidate. It develops and manufactures orthopedic biomaterials, making the collection of medical imaging data for clinical trials and mandatory post-market surveillance highly plausible. A recent majority acquisition by a PE firm to accelerate R&D and expansion serves as a strong trigger.
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
This evidence points to a collection of medical images from clinical studies and post-market surveillance, essential for training diagnostic AI to assess the real-world safety and efficacy of bone cements.
Industrial data
This represents proprietary time-series data from the mechanical and chemical testing of orthopedic products, offering a unique ground-truth dataset for AI models predicting material performance and failure.
Regulatory records
This consists of regulatory text documents demonstrating ISO 13485 compliance and CE marking, which validates the data's commercial-grade origin and provides critical context for any AI solution seeking its own regulatory approval.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Coverage
Scanned sources
Deliverable
Premium dataset report
G 21 Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Diagnostics market = $1.64 billion in 2023, CAGR 26.40% (source: BlueWeave Consulting). Investment score 42.5/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Markennovy — Medical Imaging Dataset Opportunity
View opportunity →healthcareEndiatx — Medical Imaging Dataset Opportunity
View opportunity →healthcareAktiia — Sensor Telemetry Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- Is Your Data Worth Money?3 min read
- What is a Dataset Worth?3 min read
- How a Data Transaction Works3 min read